Business Context and Reporting Period
This Form 8-K Current Report was filed by Milestone Pharmaceuticals Inc. on September 9, 2019. The filing discloses the appointment of new executive officers and related compensatory arrangements. The Company is an emerging growth company incorporated in Québec, with its principal executive offices in Montréal.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and employment terms.
Material Changes
The primary material change reported is the appointment of two senior executives effective September 9, 2019:
- Amit Hasija was appointed Chief Financial Officer and Executive Vice President of Corporate Development.
- Timothy L. Maness was appointed Chief Accounting Officer, continuing his role as Vice President, Finance.
Compensatory Arrangements and Management Commentary
The filing details the employment terms for the newly appointed officers:
- Amit Hasija Compensation:
- Annual base salary: $390,000.
- Target performance bonus: Up to 35% of gross base salary.
- Equity: Option to purchase 147,000 common shares at an exercise price of $22.45 per share (closing price on September 9, 2019).
- Vesting: 25% on the one-year anniversary, with the remainder vesting in equal monthly installments over four years.
- Severance: Nine months of salary continuation and health benefits upon termination without cause or resignation for good reason. In the event of a change in control, severance increases to 12 months plus a one-time bonus and accelerated vesting of options.
- Timothy L. Maness Compensation:
- Equity: Additional option to purchase 20,000 common shares at an exercise price of $22.45 per share.
- Vesting: 25% on the one-year anniversary, with the remainder vesting in equal monthly installments over four years.
Both employment agreements are at-will with no specified term. The Company issued a press release regarding these appointments, which is incorporated by reference.
Investor Verification Checklist
- Verify the vesting schedule and exercise price ($22.45) for the 147,000 options granted to Amit Hasija and the 20,000 options granted to Timothy L. Maness.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause," "good reason," and "change in control."
- Confirm the Company's cash position to ensure it can support the new executive compensation structure, as this filing does not provide current liquidity data.
- Check subsequent filings for any updates to the Company's pipeline or financial status, as this 8-K contains no operational or financial results.